Remove 2023 Remove Drugs Remove Packaging Remove Pharmacy
article thumbnail

DrugBank adds ASHP data to knowledgebase, improving user experience and data reliability

DrugBank

EDMONTON, CANADA, November 1st, 2023— DrugBank today kicked off their role as a key distributor of the American Society for Health-System Pharmacists’s (ASHP) data. Discover ASHP Third-Party Packages in the Data Librar y ABOUT DRUGBANK DrugBank is the world’s first intelligent and comprehensive drug knowledge platform.

article thumbnail

Scandinavia: insight into opportunities for drug discovery

Drug Discovery World

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. DDW Volume 24 – Issue 1, Winter 2022/2023 Reference [link] The post Scandinavia: insight into opportunities for drug discovery appeared first on Drug Discovery World (DDW).

Science 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

On January 31 2023, an internally circulated version of the European Commission’s overhaul of the EU’s pharma legislation was leaked, and published by Politico 1. Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2.

article thumbnail

Analysis Life Sciences Thank You Ahead of a November deadline, FDA finalizes guidance on waivers, exemptions or exceptions from supply chain security requirements

Agency IQ

Ahead of a November deadline, FDA finalizes guidance on waivers, exemptions or exceptions from supply chain security requirements In a busy week for Drug Supply Chain Security Act (DSCSA) policy updates, the FDA finalized new guidance on waivers, exceptions or exemptions (WEE) from requirements under the DSCSA.

FDA 40
article thumbnail

CMS Final Medicaid Drug Rebate Rule Details New Misclassification Penalties and Numerous Other Changes

FDA Law Blog: Biosimilars

Gaulkin — In May 2023, we posted about a CMS proposed regulation that sought to make a wide variety of changes to the Medicaid Drug Rebate Program (MDRP), including a new “price verification survey,” and a controversial proposal to require “stacking” of discounts to different customers when determining best price. See 42 U.S.C.

article thumbnail

Analysis Life Sciences Thank You After 13-year review, FDA finalizes ‘clear, conspicuous and neutral’ drug advertising rule

Agency IQ

The changes, which should take effect in mid-2024, should result in drug ads with fewer distracting elements and more emphasis on the major risks of the drug. These requirements are further established under 21 CFR 202.1 , which outline FDA’s expectations for prescription drug advertising.

FDA 40
article thumbnail

What is Special about September 24, 2023 for the UDI System?

FDA Law Blog: Biosimilars

Such codes need to be placed on device labels and packages to allow devices to be easily identified and tracked throughout their lifecycle, except where the rule provided for an exception or alternative. So, what is special about September 24, 2023? Devices can have both a UPC code and a UDI on their label and package.